will buy in a deal valued at $5.2 billion, net of cash, for access to Anacor's non-steroidal topical gel to treat eczema.
Shares of Anacor soared more than 50 percent in...
More
will buy in a deal valued at $5.2 billion, net of cash, for access to Anacor's non-steroidal topical gel to treat eczema.
Shares of Anacor soared more than 50 percent in...